Review
Version 1
Preserved in Portico This version is not peer-reviewed
Calcineurin Inhibitors in Atopic Dermatitis
Version 1
: Received: 1 May 2024 / Approved: 1 May 2024 / Online: 1 May 2024 (07:49:16 CEST)
How to cite: Janagond, A. B.; Inamadar, A. C. Calcineurin Inhibitors in Atopic Dermatitis. Preprints 2024, 2024050059. https://doi.org/10.20944/preprints202405.0059.v1 Janagond, A. B.; Inamadar, A. C. Calcineurin Inhibitors in Atopic Dermatitis. Preprints 2024, 2024050059. https://doi.org/10.20944/preprints202405.0059.v1
Abstract
Atopic dermatitis (AD) is a chronic inflammatory condition which significantly affects quality of life in both patients and their caregivers. Calcineurin inhibitors (CNI) are a class of immunosuppressive drugs predominantly inhibiting T cell mediated immune processes. CNI form complex by binding with immunophilins and in turn inhibit calcineurin and suppress downstream inflammatory pathway. Tacrolimus and pimecrolimus are topical CNI approved for the treatment of mild to severe AD in both children and adults. Application site reactions are frequently seen. They have been issued with black box warning towards increased risk of malignancies but supportive evidence is lacking. Cyclosporine, though highly effective, is used off-label for AD management. It is used for controlling acute flares of AD due to its very rapid onset of action. Nephrotoxicity and hypertension are its serious complications. CNI have not been reported with teratogenicity and may be used conditionally during pregnancy and lactation.
Keywords
atopic dermatitis; calcineurin; NFAT; tacrolimus; pimecrolimus; cyclosporine
Subject
Medicine and Pharmacology, Dermatology
Copyright: This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Comments (0)
We encourage comments and feedback from a broad range of readers. See criteria for comments and our Diversity statement.
Leave a public commentSend a private comment to the author(s)
* All users must log in before leaving a comment
